摘要
2例肿瘤患者口服优福定(UFT)4片,其血清FT-207浓度及药代学参数存在明显个体差异。124只肝癌腹水型实体瘤小鼠服用UFT50、40和31mg/kg/d×8d,最低稳态血药浓度亦有相似的个体差异。将荷瘤鼠按血清FT-207浓度分组,其血药浓度与T/C值和第3、6、8天的体重增长率均显著相关,相关系数r分别为-0.9557(P<0.0005)、-0.8936(P<0.005)、-0.9795(P<0.Q005)和-0.9770(P<0.0005)。使T/C值为50％或实验始末维持体重不变的FT-207浓度分别为3.03和3.09μg/ml。文中讨论了监测血清FT-207浓度的必要性及其临床意义。
When two patiets with carcinoma orally admini- stered a single dose of 200mg UFT tablets, their concentration of ftorrafur in serum and pharmacokinetical parameters showed mar ked individual variation. Similar individual variation of minimal concentration of ftorafur in serum during plateau state were ob- served when UFT (50, 40 and 31 mg/kg) was intragastric adminis- tered once a day for eight days in 125 mice with carcinoma pullulans of HepA. If the mice were regrouped based on their serum level of ftorafur, the antitumour effects of UFT and the growing rate of mice weight (WGR) in the third, sixth and eighth day of experi- ment showed marked relation with serum level of ftorafur. Their correlative coefficients were -0.9557, -0,8936, -0.9795 and -0.9770, respectively, The concentrations that T/C equaled 50 per cent and WGR equaled zero by the end of the experiment were 3.03 and 3.09ug/ml, respectively, The necessity and clinical significance monitoring ftorafur level in serum are discussed in the paper.
出处
《泰山医学院学报》
CAS
1991年第1期38-43,共6页
Journal of Taishan Medical College
关键词
抗癌药物
优福定
药代动力学
UFT
Ftorafur
Serum druglevel
Pharmacokineties
Individual Variation Dose-effect relationship
Cancer
